Kemwell Pvt Ltd, a leading contract manufacturer of formulations has entered into a strategic agreement with Patheon, a global provider of drug development and manufacturing services.

The alliance allows Bangalore-based Kemwell and Patheon to refer and market each others' services to the respective clients requirements. The alliance is effective immediately and full promotion by Patheon's business development units is expected by mid-year.

"This alliance gives us more flexibility in our service offering. With Kemwell's GMP facility and expertise, we can offer our clients low volume, low cost solutions in solid, semi-solid and liquid dosage form manufacturing, and a full range of formulation and CMC-related development services from a new base in India," said Wes Wheeler, chief executive officer and president, Patheon Inc.

"Patheon's aseptic and high-potent manufacturing expertise brings an important capability to Kemwell's portfolio of services," said Anurag Bagaria, vice-president Business Development of Kemwell Pvt Ltd. "We look forward to actively and cooperatively meeting and exceeding our respective client's requirements."

For over two decades, Kemwell has been a dedicated provider of formulations, contract manufacturing and development services for multinational pharma companies. The company's customers include five of the top 10 pharmaceutical companies in the world, manufacturing fine of the top 10 brands in India. From facilities in India and Sweden, Kemwell manufactures tablets, capsules, liquid orals, external drops, ointments, gels and creams. Its Pharmaceutical Development Unit provides services in clinical manufacturing and packaging, formulation and analytical development, stability studies, regulatory documentation etc. With a cent per cent commitment to pure play contract manufacturing, Kemwell has no branded products of its own in the market, thereby avoiding any conflict of interests with its customers.

Patheon is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. It serves more than 300 of the world's leading pharmaceutical and biotechnology companies in services ranging from preclinical development through commercial manufacturing of a full array of dosage forms. These include parenteral, solid, semi-solid and liquid forms. Among its innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. The company can take customers direct to clinic with global clinical packaging and distribution services. Its Patheon's Quick to Clinic programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API. It has a manufacturing network of 10 facilities and 6 development centers across North America and Europe.